TipRanks
Henry Schein (CH:HS2)
:HS2
Switzerland Market
HS2
Henry Schein
RESEARCH TOOLSreports

Henry Schein (HS2) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HS2 Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
9 Buy
5 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Henry
Schein
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HS2 Stock 12 Month Forecast

Average Price Target

―
Based on 14 Wall Street analysts offering 12 month price targets for Henry Schein in the last 3 months. The average price target is CHF84.24 with a high forecast of CHF93.20 and a low forecast of CHF70.73. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF93.20Average Price TargetCHF84.24Lowest Price TargetCHF70.73
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:HS2
Allen Lutz
Bank of America Securities
Bank of America Securities
CHF74.89→CHF91.54
Buy
―
Reiterated
10/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barrington Analyst forecast on CH:HS2
Michael Petusky
Barrington
Barrington
CHF86.55
Buy
―
Reiterated
10/01/26
Analysts Have Conflicting Sentiments on These NA Companies: Henry Schein (NASDAQ: HSIC), Forrester Research (NASDAQ: FORR) and Kadant (NYSE: KAI)
Piper Sandler Analyst forecast on CH:HS2
Jason Bednar
Piper Sandler
Piper Sandler
CHF79.06→CHF86.55
Buy
―
Reiterated
09/18/26
Piper Sandler Remains a Buy on Henry Schein (HSIC)
BTIG Analyst forecast on CH:HS2
David Larsen
BTIG
BTIG
CHF83.22→CHF91.54
Buy
―
Reiterated
08/19/26
BTIG Sticks to Their Buy Rating for Henry Schein (HSIC)
J.P. Morgan Analyst forecast on CH:HS2
John Stansel
J.P. Morgan
J.P. Morgan
CHF84.88
Buy
―
Reiterated
08/06/26
J.P. Morgan Keeps Their Buy Rating on Henry Schein (HSIC)
Robert W. Baird Analyst forecast on CH:HS2
Jeff Johnson
Robert W. Baird
Robert W. Baird
CHF80.72→CHF90.71
Buy
―
Reiterated
08/05/26
Henry Schein price target raised to $109 from $97 at BairdHenry Schein price target raised to $109 from $97 at Baird
Stifel Nicolaus Analyst forecast on CH:HS2
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
CHF69.9→CHF79.06
Hold
―
Reiterated
08/05/26
Henry Schein price target raised to $95 from $84 at StifelHenry Schein price target raised to $95 from $84 at Stifel
UBS Analyst forecast on CH:HS2
Kevin Caliendo
UBS
UBS
CHF74.06→CHF78.22
Hold
―
Reiterated
08/05/26
Henry Schein price target raised to $94 from $89 at UBSHenry Schein price target raised to $94 from $89 at UBS
Barclays Analyst forecast on CH:HS2
Glen Santangelo
Barclays
Barclays
CHF71.57→CHF83.22
Buy
―
Reiterated
08/05/26
Barclays Remains a Buy on Henry Schein (HSIC)
Citi Analyst forecast on CH:HS2
Daniel Grosslight
Citi
Citi
CHF83.22→CHF93.2
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)
Mizuho Securities Analyst forecast on CH:HS2
Steven Valiquette
Mizuho Securities
Mizuho Securities
CHF68.24→CHF71.57
Hold
―
Reiterated
08/05/26
Henry Schein price target raised to $86 from $82 at MizuhoHenry Schein price target raised to $86 from $82 at Mizuho
Evercore ISI Analyst forecast on CH:HS2
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF74.89→CHF87.38
Buy
―
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Henry Schein (HSIC)
BMO Capital Analyst forecast on CH:HS2
Vik Chopra
BMO Capital
BMO Capital
CHF70.73
Hold
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Addus Homecare (NASDAQ: ADUS) and Henry Schein (NASDAQ: HSIC)
William Blair Analyst forecast on CH:HS2
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Danaher (NYSE: DHR) and Henry Schein (NASDAQ: HSIC)
Morgan Stanley Analyst forecast on CH:HS2
Erin Wright
Morgan Stanley
Morgan Stanley
CHF50.76→CHF53.26
Sell
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on CH:HS2
Allen Lutz
Bank of America Securities
Bank of America Securities
CHF74.89→CHF91.54
Buy
―
Reiterated
10/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Barrington Analyst forecast on CH:HS2
Michael Petusky
Barrington
Barrington
CHF86.55
Buy
―
Reiterated
10/01/26
Analysts Have Conflicting Sentiments on These NA Companies: Henry Schein (NASDAQ: HSIC), Forrester Research (NASDAQ: FORR) and Kadant (NYSE: KAI)
Piper Sandler Analyst forecast on CH:HS2
Jason Bednar
Piper Sandler
Piper Sandler
CHF79.06→CHF86.55
Buy
―
Reiterated
09/18/26
Piper Sandler Remains a Buy on Henry Schein (HSIC)
BTIG Analyst forecast on CH:HS2
David Larsen
BTIG
BTIG
CHF83.22→CHF91.54
Buy
―
Reiterated
08/19/26
BTIG Sticks to Their Buy Rating for Henry Schein (HSIC)
J.P. Morgan Analyst forecast on CH:HS2
John Stansel
J.P. Morgan
J.P. Morgan
CHF84.88
Buy
―
Reiterated
08/06/26
J.P. Morgan Keeps Their Buy Rating on Henry Schein (HSIC)
Robert W. Baird Analyst forecast on CH:HS2
Jeff Johnson
Robert W. Baird
Robert W. Baird
CHF80.72→CHF90.71
Buy
―
Reiterated
08/05/26
Henry Schein price target raised to $109 from $97 at BairdHenry Schein price target raised to $109 from $97 at Baird
Stifel Nicolaus Analyst forecast on CH:HS2
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
CHF69.9→CHF79.06
Hold
―
Reiterated
08/05/26
Henry Schein price target raised to $95 from $84 at StifelHenry Schein price target raised to $95 from $84 at Stifel
UBS Analyst forecast on CH:HS2
Kevin Caliendo
UBS
UBS
CHF74.06→CHF78.22
Hold
―
Reiterated
08/05/26
Henry Schein price target raised to $94 from $89 at UBSHenry Schein price target raised to $94 from $89 at UBS
Barclays Analyst forecast on CH:HS2
Glen Santangelo
Barclays
Barclays
CHF71.57→CHF83.22
Buy
―
Reiterated
08/05/26
Barclays Remains a Buy on Henry Schein (HSIC)
Citi Analyst forecast on CH:HS2
Daniel Grosslight
Citi
Citi
CHF83.22→CHF93.2
Buy
―
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (NASDAQ: PCRX), BioNTech SE (NASDAQ: BNTX) and Henry Schein (NASDAQ: HSIC)
Mizuho Securities Analyst forecast on CH:HS2
Steven Valiquette
Mizuho Securities
Mizuho Securities
CHF68.24→CHF71.57
Hold
―
Reiterated
08/05/26
Henry Schein price target raised to $86 from $82 at MizuhoHenry Schein price target raised to $86 from $82 at Mizuho
Evercore ISI Analyst forecast on CH:HS2
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF74.89→CHF87.38
Buy
―
Reiterated
08/04/26
Evercore ISI Keeps Their Buy Rating on Henry Schein (HSIC)
BMO Capital Analyst forecast on CH:HS2
Vik Chopra
BMO Capital
BMO Capital
CHF70.73
Hold
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Addus Homecare (NASDAQ: ADUS) and Henry Schein (NASDAQ: HSIC)
William Blair Analyst forecast on CH:HS2
Brandon Vazquez
William Blair
William Blair
―
Hold
―
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Danaher (NYSE: DHR) and Henry Schein (NASDAQ: HSIC)
Morgan Stanley Analyst forecast on CH:HS2
Erin Wright
Morgan Stanley
Morgan Stanley
CHF50.76→CHF53.26
Sell
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
EHCEncompass Health
OVIDOvid Therapeutics
IMUXImmunic
ATECAlphatec Holdings
CELCCelcuity
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Henry Schein

3 Months
Michael PetuskyBarrington
Success Rate
20/37 ratings generated profit
54%
Average Return
+2.38%
Copying Michael Petusky's trades and holding each position for 3 Months would result in 54.05% of your transactions generating a profit, with an average return of +2.38% per trade.
1 Year
Allen LutzBank of America Securities
Success Rate
12/18 ratings generated profit
67%
Average Return
+7.54%
Copying Allen Lutz's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +7.54% per trade.
2 Years
Allen LutzBank of America Securities
Success Rate
12/18 ratings generated profit
67%
Average Return
+9.86%
Copying Allen Lutz's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +9.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HS2 Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
11
11
13
12
12
Hold
6
7
7
7
5
Sell
2
1
0
0
0
Strong Sell
0
0
0
0
0
total
19
19
20
19
17
In the current month, HS2 has received 12 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. HS2 average Analyst price target in the past 3 months is 84.24.
Each month's total comprises the sum of three months' worth of ratings.

HS2 Financial Forecast

HS2 Earnings Forecast

Next quarter’s earnings estimate for HS2 is CHF1.14 with a range of CHF1.08 to CHF1.21. The previous quarter’s EPS was CHF1.06. HS2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for HS2 is CHF1.14 with a range of CHF1.08 to CHF1.21. The previous quarter’s EPS was CHF1.06. HS2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.

HS2 Sales Forecast

Next quarter’s sales forecast for HS2 is CHF2.89B with a range of CHF2.85B to CHF2.92B. The previous quarter’s sales results were CHF2.88B. HS2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.
Next quarter’s sales forecast for HS2 is CHF2.89B with a range of CHF2.85B to CHF2.92B. The previous quarter’s sales results were CHF2.88B. HS2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.

HS2 Stock Forecast FAQ

What is CH:HS2’s average 12-month price target, according to analysts?
Based on analyst ratings, Henry Schein’s 12-month average price target is 84.24.
    What is CH:HS2’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:HS2, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Henry Schein a Buy, Sell or Hold?
        Henry Schein has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.
          What is Henry Schein’s share price target?
          The average share price target for Henry Schein is 84.24. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF93.20 ,and the lowest forecast is CHF70.73. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Henry Schein?
            Henry Schein’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
              How can I buy shares of Henry Schein?
              To buy shares of CH:HS2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.